logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Trick or Trade

Promising Stocks in the First Two Trading Days of 2023

The Stock Market in the New Year It is still too early to tell how the stock market will perform in 2023. However, o n Tuesday January 3, 2023 (the first market trading day in 2023), most biotech stocks plummeted,...

Read More

January 4, 2023

0

Stocks Outperforming Today

January 5, 2023 In Today's Down Market the stocks that are outperforming are as follows: Reata Pharmaceuticals ( RETA ) bluebird bio Inc ( BLUE ) And Vertex Pharmaceuticals ( VRTX ) ...

Read More

January 5, 2023

0

Could We Soon Have a Specific Treatment for the Rare Disease IgA Nephritis?

It's Time to Remind About Travere Therapeutics The time has come to remind that the U.S. FDA is reviewing Travere Therapeutics’ ( TVTX ) New Drug Application ( NDA ) under Subpart H for accelerated approval of sparsentan for IgA...

Read More

February 2, 2023

0

Xenon Pharmaceuticals: A Newly Selected Clinical-Stage Firm. See Also: Recently Selected Clinical Stage Firms

Xenon Pharmaceuticals Xenon Pharmaceuticals ( XENE ) - a clinical stage biopharmaceutical company developing novel  treatments aimed at improving the lives of patients with neurological disorders. The firm is advancing its neurology pipeline to address diseases with unmet medical need. The...

Read More

February 7, 2023

0

Endogena Therapeutics: Treating Retinitis Pigmentosa and Other Devastating Degenerative Diseases

Endogena Therapeutics The US FDA designated Fast Track development program for the investigation of Endogena Therapeutics' product EA-2353 for the treatment of Retinitis Pigmentosa ( RP ). The Fast Track is a process designed to enable patients to benefit earlier...

Read More

February 8, 2023

0

Why the Current Interest in Ventyx Biosciences

The Current Interest in Ventyx Biosciences Answered 1. Ventyx Biosciences Focus   We like the fact that Ventyx Biosciences ( VTYX ) is not just focusing on developing innovative oral Drugs for people living with autoimmune and inflammatory disorders, but also...

Read More

March 7, 2023

0

Our Eyes Are on Reata Pharmaceuticals Today

Eye on Reata Pharmaceuticals Recently, Reata Pharmaceuticals ( RETA ) announced a setback of its chronic kidney disease product known as bardoxolone. The failure of this drug occurred after Reata's product Skyclaris was FDA approved for the treatment of Friedrich's...

Read More

May 25, 2023

0

Immunovent, Altimmune and Soleno: A Summary of Three Firms We Believe Have Promising Technologies and Treatments

Immunovent, Altimmune & Soleno In addition to Vertex ( VRTX ) , Crispr Therapeutics ( CRSP )  and Acturus Therapeutics ( ARCT ) , the following summaries are of three firms we believe have promising Products  1. Immunovent The phase...

Read More

December 27, 2023

0

Vertex Pharmaceuticals Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings

Vertex Pharmaceuticals Updates Vertex Pharmaceuticals ( VRTX ) announced multiple program updates ahead of the upcoming investor meetings in January, including the 42 Annual J.P. Morgan Healthcare Conference, which took place on January 8, 2024. From Vertex Pharmaceuticals Reshma Kewalramani,...

Read More

January 9, 2024

0

OKYO Pharma Limited: Another Ophthalmology Firm with Promising Eye Treatment

Improving eyesight is speeding towards treating devastating eye diseases from the Retina in the back of the eye to the cornea on the front surface of the eye. As we wrote in Prohost Letter #457 , the current biotechnology revolution...

Read More

January 11, 2024

0

  • Previous
  • 1
  • 2
  • ...
  • 15
  • 16
  • 17
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy